Loading...
XHKG8049
Market cap100mUSD
Dec 23, Last price  
1.40HKD
1D
0.00%
1Q
7.69%
Jan 2017
-13.58%
Name

Jilin Province Huinan Changlong Bio-pharmacy Co Ltd

Chart & Performance

D1W1MN
XHKG:8049 chart
P/E
4.97
P/S
0.88
EPS
0.26
Div Yield, %
36.17%
Shrs. gr., 5y
—
Rev. gr., 5y
5.38%
Revenues
842m
0.00%
83,986,00081,889,00069,522,00097,284,000127,124,000152,766,000200,630,000274,294,000353,247,000457,746,000601,715,000539,134,000654,119,000645,303,000647,672,000645,885,000622,250,000705,456,000841,586,000841,545,000
Net income
148m
-23.43%
8,603,0008,017,0003,037,00012,378,00014,989,00022,076,00035,891,00050,893,00058,754,00079,274,000132,785,000117,638,000142,670,000144,402,000161,216,000144,726,000126,558,000143,283,000193,565,000148,207,000
CFO
316m
+54.88%
12,872,00017,841,00029,357,00017,096,00040,643,00014,397,00055,169,00022,909,00050,893,00082,694,00049,434,000151,613,000123,823,000146,507,000138,813,000132,509,000151,227,000215,090,000203,992,000315,947,000
Dividend
Jun 18, 20240.06862 HKD/sh
Earnings
Mar 26, 2025

Profile

Jilin Province Huinan Changlong Bio-pharmacy Company Limited engages in the manufacture and distribution of Chinese medicines and pharmaceutical products in the People's Republic of China. It offers tablets, capsules, pills, Chinese medicine pretreatment and extraction products, powders for injections, lyophilized powder for injections, small volume injection solutions, APIs, and granules. The company markets its products under the Changlong and Qing Tong brands. The company was formerly known as Jilin Province Huinan Biochemical Pharmaceutical Company Limited. Jilin Province Huinan Changlong Bio-pharmacy Company Limited was founded in 1989 and is based in Kowloon, Hong Kong.
URL
http://www.jlchanglong.com
IPO date
May 24, 2001
Employees
928
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
841,545
0.00%
841,586
19.30%
705,456
13.37%
Cost of revenue
719,910
722,561
600,033
Unusual Expense (Income)
NOPBT
121,635
119,025
105,423
NOPBT Margin
14.45%
14.14%
14.94%
Operating Taxes
50,107
3,780
33,990
Tax Rate
41.19%
3.18%
32.24%
NOPAT
71,528
115,245
71,433
Net income
148,207
-23.43%
193,565
35.09%
143,283
13.22%
Dividends
(283,670)
(28,218)
(26,358)
Dividend yield
30.87%
5.79%
3.99%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
8,400
400
400
Long-term debt
72,000
Deferred revenue
40,966
41,954
Other long-term liabilities
41,155
1,961
953
Net debt
(1,299,348)
(324,606)
(831,388)
Cash flow
Cash from operating activities
315,947
203,992
215,090
CAPEX
(31,841)
(11,317)
(92,835)
Cash from investing activities
109,043
(117,971)
(160,614)
Cash from financing activities
(186,454)
(27,714)
(25,199)
FCF
304,627
130,425
(42,397)
Balance
Cash
655,591
1,032,126
262,251
Long term investments
724,157
(707,120)
569,537
Excess cash
1,337,671
282,927
796,515
Stockholders' equity
1,396,040
1,527,958
1,369,409
Invested Capital
264,264
1,314,473
634,312
ROIC
9.06%
11.83%
10.76%
ROCE
7.59%
7.44%
7.35%
EV
Common stock shares outstanding
560,250
560,250
560,250
Price
1.64
88.51%
0.87
-26.27%
1.18
-4.84%
Market cap
918,810
88.51%
487,418
-26.27%
661,095
-4.84%
EV
(380,538)
162,812
(170,293)
EBITDA
149,195
152,629
134,301
EV/EBITDA
1.07
Interest
515
477
344
Interest/NOPBT
0.42%
0.40%
0.33%